Comparison of efficacy of intramuscular meglumine antimoniate plus oral allopurinol with intramuscular meglumine antimoniate alone in treatment of cutaneous leishmaniasis

Phase 3

Recruiting

• Conditions: Cutaneous leishmaniasis.; Cutaneous leishmaniasis; B55.1

• Registration Number: IRCT20210823052264N6
• Lead Sponsor: CMH Quetta

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

All patients with biopsy proven leishmaniasis or has lesion(s) located in sites not compatible with local treatment for example lesions on or around eyes
Disfiguring lesion on face that lead to scarring
Lesions difficult to heal like on lower limbs
Lesion more than 4cm in size with sporotichoid spread
Multiple lesions

Exclusion Criteria

patients allergic to antimonials
Pregnant and breast feeding patients
Patients having mucosal, mucocutaneous or visceral leishmaniasis
Patients with comorbids (diabetes, hypertension, chronic liver disease, chronic kidney disease)
Immunosuppression patients
Baseline ECG abnormalities/heart disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Healing of lesion in response to treatment. Timepoint: before intervention and 2, 4 , 6 and 8 weeks after intervention until complete healing occurs then patient called for followup after 4 weeks. Method of measurement: Clinical response.